Virtual Library

Start Your Search

Vaida Gedvilaite

Author of

  • +

    P1.15 - Treatment in the Real World - Support, Survivorship, Systems Research (Not CME Accredited Session) (ID 947)

    • Event: WCLC 2018
    • Type: Poster Viewing in the Exhibit Hall
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 9/24/2018, 16:45 - 18:00, Exhibit Hall
    • +

      P1.15-09 - Trends in Lung Cancer Survival in Lithuania (ID 11138)

      16:45 - 18:00  |  Presenting Author(s): Vaida Gedvilaite

      • Abstract
      • Slides


      Lung cancer is the most common cancer-related death worldwide. The prognosis of lung cancer is unfavourable and improvements in survival in recent decades have been minimal. The aim of this study is to describe the most recent survival rates by sex, age group, extent of disease and histology of lung cancer in Lithuania.

      a9ded1e5ce5d75814730bb4caaf49419 Method

      The study is based on the Lithuanian Cancer Registry database covering a population of around 3 million residents according to 2011 census. The analysis included patients with primary invasive lung cancer diagnosed in 1998-2012 who were at least 15 years old at the time of diagnosis. Patients were followed-up with respect to vital status until December 31, 2012. Cases notified by the death certificate only were excluded. Five-year relative survival estimates were calculated using period analysis. Relative survival was calculated as the ratio of the observed survival of cancer patients and the expected survival of the underlying general population. The latter was calculated according to the Ederer II method using national life tables for Lithuanian population stratified by age, gender and calendar year.

      4c3880bb027f159e801041b1021e88e8 Result

      In our study the overall 5-year relative survival was low, but increased slightly from 6,4% in 2003-2008 to 7.9 % 2009-2012. Positive changes in survival were evident in both sexes, in almost all age groups and for all histological groups and disease stages. Adenocarcinoma relative survival increased from 6.7% in 2003-2008 to 12.8% in 2009-2012 and squamous cell carcinoma increased from 7.4% in 2003-2008 to 11.1% in 2009-2012. Patients with small cell carcinoma had the worst survival (2.9% in 2003-2008 and 3.6% in 2009-2012). Only less than 10% of lung cancer cases were diagnosed localised and proportion of those tumours decreased slightly (from 8.5% to 7.6%). In 2009-2012 relative survival of localised stage lung cancer was 43 %, locally advanced – 19,9%, regional disease - 6% and metastatic disease – 0.7%.The highest number of lung cancer was diagnosed with distant metastases and proportion of metastatic tumours increased from 35.1% to 37.8%. 5-year relative survival was higher in women (9.4 % in 2003-2008 and 12.6 % in 2009-2012) than in men (5.8 % in 2003-2008 and 7% in 2009-2012).

      8eea62084ca7e541d918e823422bd82e Conclusion

      Despite low overall survival, there were positive changes in survival in both sexes, in almost all age groups and for all histological groups and disease stages. The high proportion of metastatic disease at the time of diagnosis was the main factor that influenced low survival rates.


      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.